APOBEC3B与PRC2相互作用调节微环境促进肝细胞癌进展
该研究探讨了APOBEC3B(A3B)在肝细胞癌(HCC)中上调的机制及其对肿瘤微环境的影响。研究发现A3B通过非经典NF-κB信号通路上调,并以脱氨酶非依赖的方式与PRC2相互作用,降低全局H3K27me3丰度及CCL2启动子上的H3K27me3占据,从而招募TAMs和MDSCs促进HCC生长;CCR2拮抗剂可抑制该过程并延缓肿瘤生长。
要点
- A3B通过非经典NF-κB信号通路上调,促进免疫健全小鼠HCC生长。
- A3B与PRC2相互作用降低H3K27me3,减少CCL2启动子占据,招募TAMs和MDSCs。
- CCR2拮抗剂可抑制TAMs和MDSCs浸润并延缓A3B表达肿瘤生长。
核心结论
- A3B以脱氨酶非依赖的方式调节HCC微环境,靶向A3B可能为HCC免疫治疗提供依据。
研究设计与样本
- 采用A3B启动子荧光素酶报告基因等技术阐明A3B在HCC中上调的机制;构建A3B过表达和敲低细胞模型,在免疫健全和免疫缺陷小鼠HCC模型中研究A3B对HCC进展的影响;通过RNA-seq、流式细胞术等分析A3B调节细胞因子招募MDSCs和TAMs的机制。
主要发现
- A3B上调通过非经典NF-κB信号通路促进免疫健全小鼠HCC生长,伴随MDSCs、TAMs和表达PD1的CD8+ T细胞增加。
- CCR2拮抗剂抑制A3B及A3BE68Q/E255Q表达小鼠肿瘤中TAMs和MDSCs浸润并延缓肿瘤生长。
- A3B上调通过与PRC2相互作用降低全局H3K27me3丰度,并减少H3K27me3在趋化因子CCL2启动子上的占据,从而招募大量TAMs和MDSCs。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: APOBEC3B (A3B), a cytidine deaminase acting as a contributor to the APOBEC mutation pattern in many kinds of tumours, is upregulated in patients with hepatocellular carcinoma (HCC). However, APOBEC mutation patterns are absent in HCC. The mechanism of how A3B affects HCC progression remains elusive. DESIGN: A3B -promoter luciferase reporter and other techniques were applied to elucidate mechanisms of A3B upregulation in HCC. A3B overexpression and knockdown cell models, immunocompetent and immune-deficient mouse HCC model were conducted to investigate the influence of A3B on HCC progression. RNA-seq, flow cytometry and other techniques were conducted to analyse how A3B modulated the cytokine to enhance the recruitment of myeloid--derived suppressor cells (MDSCs) and tumour--associated macrophages (TAMs). RESULTS: A3B upregulation through non-classical nuclear factor-κB (NF-κB)signalling promotes HCC growth in immunocompetent mice, associated with an increase of MDSCs, TAMs and programmed cell death1 (PD1) exprssed CD8+ T cells. A CCR2 antagonist suppressed TAMs and MDSCs infiltration and delayed tumour growth in A3B and A3BE68Q/E255Q- expressing mouse tumours. Mechanistically, A3B upregulation in HCC depresses global H3K27me3 abundance via interaction with polycomb repressor complex 2 (PRC2) and reduces an occupancy of H3K27me3 on promoters of the chemokine CCL2 to recruit massive TAMs and MDSCs. CONCLUSION: Our observations uncover a deaminase-independent role of the A3B in modulating the HCC microenvironment and demonstrate a proof for the concept of targeting A3B in HCC immunotherapy.
引用
- Wang D, Li X, Li J, et al. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut. 2019. PMID: 31154396. doi:10.1136/gutjnl-2018-317601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。